Madrigal Pharmaceuticals, Inc. (MDGL) Dividend History

Company News

• Madrigal (MDGL) Q2 Revenue Soars 1,313%

  Madrigal Pharmaceuticals reported strong Q2 2025 performance, with GAAP revenue of $212.8 million for its MASH therapy Rezdiffra, exceeding estimates by 31.3%. The company saw rapid patient adoption, with over 23,000 patients on the drug and expanding commercial operations.

  The Motley Fool
• Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

  Madrigal Pharmaceuticals will release its Q2 2025 financial results on August 5, 2025, and host a live webcast at 8 a.m. Eastern Time to review financial and operating results.

  GlobeNewswire Inc.

  Featured Companies: OBDC
• Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

  Madrigal Pharmaceuticals reported positive two-year data for its drug Rezdiffra in treating compensated MASH cirrhosis, showing significant reductions in liver stiffness. The company also reported better-than-expected Q4 financial results.

  Benzinga
• Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings? - Zacks Investment Research

  Viking Therapeutics, a biotech firm without any marketed drugs, is set to report its Q2 earnings. Investors will focus on updates related to its pipeline candidates, including VK2809 for NASH and VK2735 for obesity. The company's strong cash balance and robust pipeline development provide growth potential, though it faces competition in the obesity market.

  Zacks Investment Research

  Featured Companies: LLY VKTX
• Madrigal’s stock surges as FDA approves first drug for liver disease MASH

  Madrigal Pharmaceuticals on Thursday received the FDA’s first approval of a drug designed to treat a severe liver disease known as MASH.

  MarketWatch

  Featured Companies: AKRO ETNB LLY